Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients

Experimental and Toxicologic Pathology

Volumn 54, Issue 5-6, 2003, Pages 493-498

  Reimann, Ilselore R ^a   Meier Hellmann, Andreas ^b   Traut, Torsten ^b   Reinhart, Konrad ^b   Hoffmann, Annemarie ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Friedrich Schiller University Jena ^*

Author keywords

Bayesian estimation; Critically ill; Drug monitoring; Single blood sample; Tobramycin

Indexed keywords

CREATININE; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICAL ILLNESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG MONITORING; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MULTIPLE REGRESSION; PREDICTION; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 0038234802     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00284     Document Type: Article

References (23)

1. BECKHOUSE MJ, WHYTE IM, BYTH PL, et al.: Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988; 16: 418-422.
2. BERTINO JS, RODVOLD KA, DESTACHE CJ: Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994; 26: 71-81.
3. BLASER J, KÖNIG C, SIMMEN HP, et al.: Monitoring serum concentrations for once-daily netilmicin dosing regimens. J Antimicrob Chemotherapy 1994; 33: 341-348.
4. BRESSOLLE F, GOUBY A, MARTINEZ JM et al: Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 1996; 40: 1682-1689.
5. BURTON ME, ASH CL, HILL DP, et al.: A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 1991; 49: 685-694.
6. DAGER WE: Aminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups. Ann Pharmacother 1994; 28: 944-951.
7. DASTA JF, ARMSTRONG DK: Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16: 327-330.
8. DENARO CP, RAVENSCROFT PJ: Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients. Br J Clin Pharmacol 1989; 28: 37-44.
9. DETTLI LC: Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16: 274-280.
10. HICKLING KG, BEGG EJ, PERRY RE, et al.: Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med 1991; 19: 1041-1047.
11. HÜSLER J, ZIMMERMANN H: Statistische Prinzipien für medizinische Projekte. Hans Huber, Bern 1993.
12. LILLIEFORS HW: On the Kolmogorov-Smirnov test for normality with mean and variance unknown. J Amer Statist Assoc 1967; 62: 399-402.
13. LUGO G and CASTANEDA-HERNANDEZ G: Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997; 25: 806-811.
14. LUGO-GOYTIA G and CASTANEDA-HERNANDEZ G: Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother 2000; 34: 1389-1394.
15. MARIK PE: Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intens Care 1993; 21: 172-173.
16. MÖLLER D: Pharmacokinetic system: computer aided dosing regimens with a new software package. Int J Clin Pharmacol 1992; 30: 501-502.
17. NISHIZAWA K, HIRANO M, YAMAMURA S et al.: Prediction of plasma levels of aminoglycoside antibiotic in patients with severe illness by means of an artificial neural network simulator. J Pharmaceut Sci 1998; 1: 95-101.
18. REIMANN IR, MEIER-HELLMANN A, PFEIFER R, et al.: Serum level adjusted dosage of once-daily aminoglycoside therapy in critically ill patients: results of a prospective study. Anaesthesiol Intensivmed Notfallmed Schmerzther 1999; 34: 288-295.
19. SHEINER LB and BEAL SL: Some suggestions for measuring predictive performance. J Pharmacokinetics Biopharmaceutics 1981; 9: 503-512.
20. TANG GJ, TANG JJ, LIN BS, et al.: Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999; 43: 726-730.
21. TRIGINER C, IZQIERDO I, FERNANDEZ R, et al.: Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16: 303-306.
22. VINKS AATMM, EVERS NAEM, MATHOT RAA, et al.: Impact of goal-oriented model-based TDM of aminoglycosides in clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1997; 19: 547.
23. ZIMMERLI W, LEW DP: Use of aminoglycosides: the Swiss consensus. Schweiz Med Wochenschr 1996; 126 (suppl 76): 5S-8S.